October 15, 2008
Aruba Networks and Ipelium Selected By Galderma for Global Wireless LAN Makeover
Aruba Networks, Inc. (NASDAQ: ARUN), a global leader in wireless LANs and secure mobility solutions, today announced that Galderma has selected Aruba as its global standard for wireless LANs. Galderma, a joint venture between Nestle and L'Oreal, is an international pharmaceutical company exclusively dedicated to dermatology. Deployments have been completed at Galderma's French Corporate Services, UK office, production sites, and central data center in Switzerland by Ipelium, Aruba certified solutions provider with strong expertise in security and mobility technologies. Aruba was selected for the project based on its robust wireless LANs, ease of use, remote access capability for remote offices and teleworkers, and end-to-end security.
"Our offices and production sites are geographically dispersed, and prior to Aruba, concerns about the integrity of this far-flung network lead us to enforce a 'no wireless' policy everywhere," said Marc Tournier, Security and Compliance Manager at Galderma. "Faced with strong demand for wireless access and greater mobility, we sought a mobility solution that would protect the integrity of our data. We also wanted a solution that could be managed with minimal IT overhead yet was flexible enough to meet the different needs of our field offices and logistics facilities. Aruba offered solutions on all counts, and in conjunction with Aruba partner, Ipelium, we've now deployed wireless networks across France, the U.S., U.K., Canada and the central data center in Switzerland."
"RAP will be integral to our disaster recovery and business continuity strategy," continued Tournier. "Should an incident occur that leads to a disruption in service, RAP technology will simply and securely get our systems back on-line again."
"Aruba's solutions offer the most complete and innovative set of wireless LAN functionality on the market, and make the concept of a mobile enterprise a reality," stated Denis Confuron, Associate Director at Ipelium. "This project involved rolling out a solution to Galderma sites worldwide. Our extensive security and mobility expertise, in conjunction with great support from Aruba, allowed us to rise to the challenge. Aruba is a very good partner, and we look forward to working with them as Galderma expands their network in the months ahead."
Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is an international pharmaceutical company dedicated to the research, development and marketing of therapeutic, corrective and aesthetic solutions for dermatology patients. Galderma's expertise covers a broad spectrum of skin, hair and nail diseases, with a focus on acne, rosacea, psoriasis and steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancers and medical solutions for skin senescence. The Company is present in 65 countries with 2800 employees (among which 1000 medical sales representatives). In 2007, Galderma had global revenues of 735 million euros and committed 14.1% of revenues to R&D. With a main research and development center in Sophia Antipolis, France, Galderma has one of the largest R&D facilities devoted exclusively to dermatology.
Galderma's key brands, the drivers of the portfolio, are: Differin(R), the company's first home-grown product indicated for topical treatment of acne, Rozex(R)/MetroGel(R) 1% (rosacea), Oracea(R) (rosacea), Clobex(R) (psoriasis), Tri-Luma(R) (pigmentary disorders), Loceryl(R) (onychomycosis) and Cetaphil(R) (therapeutic skin care line). Recently launched products include Pliaglis(TM), a topical anaesthetic for dermatological procedures in the United States, Epiduo(R), an innovative combination product for the treatment of acne in Europe and Argentina and Dysport(R), a muscle relaxant (botulinum toxin type A product) for use in aesthetic medicine and dermatological indications in Brazil and Argentina. The Company's international website is www.galderma.com.
Created in 2002, Ipelium is the largest independent security solution provider in France. Ipelium remains a pure player of security and data infrastructure environment and became the first Aruba certified integrator in France in early 2003. The Ipelium technical teams (consulting, integration, development, support and maintenance) are certified for high security applications and Aruba mobility solutions. Working mainly for CAC40 large accounts, Ipelium built experience in providing long terms projects for Finance, Insurance, Health and Industry. Ipelium's web site can be visited at www.ipelium.com.
About Aruba Networks
People move. Networks must follow. Aruba securely delivers networks to users, wherever they work or roam. Our mobility solutions enable the Follow-Me Enterprise that moves in lock-step with users:
-- Adaptive 802.11a/b/g/n Wi-Fi networks optimize themselves to ensure that users are always within reach of mission-critical information; -- Identity-based security assigns access policies to users, enforcing those policies whenever and wherever a network is accessed; -- Remote networking solutions and fixed mobile convergence ensure uninterrupted access to applications as users move; -- Multi-vendor network management provides a single point of control while managing both legacy and new wireless networks from Aruba and its competitors.
The cost, convenience, and security benefits of our secure mobility solutions are fundamentally changing how and where we work. Listed on the NASDAQ and Russell 2000(R) Index, Aruba is based in Sunnyvale, California, and has operations throughout the Americas, Europe, Middle East, and Asia Pacific regions. To learn more, visit Aruba at http://www.arubanetworks.com.
Copyright 2008 Aruba Networks, Inc. AirWave(R), Aruba Networks(R), Aruba Mobility Management System(R), Bluescanner, For Wireless That Works(R), Mobile Edge Architecture, People Move. Networks Must Follow., RFProtect, The All Wireless Workplace Is Now Open For Business, Green Island, and The Mobile Edge Company(R) are trademarks of Aruba Networks, Inc. All rights reserved.
Clobex(R), Differin(R), Epiduo(R), Loceryl(R), Oracea(R), Rozex(R)/Metrogel(R) 1%, Tri-Luma(R) and Cetaphil(R) are trademarks of Galderma. Pliaglis(TM) is a trademark of Zars Pharma Inc. Dysport(R) is a trademark of Ipsen Ltd. All other trademarks are the property of their respective owners.
Media Contacts Roger Hockaday Aruba Networks EMEA +44 7760 17 40 56 [email protected] Michael Tennefoss Aruba Networks, Inc. +1-408-754-8034 [email protected] Patty Oien Breakaway Communications +1-415-358-2482 [email protected]
SOURCE: Aruba Networks, Inc.